NAFLD is the Leading Cause of Donor Rejection in Living Donor Liver Transplantation

Abstract

A b st ra ct s against Rs 1,50 000/with HBIG. In two other recipients who received HIP instead of HBIG in anhepatic phase, the mean anti HBsAb titre at end of one month was 226 + 116 IU/L; both recipients are currently on follow up. Conclusion: High titre anti HBs human plasma seems to show a promising outcome, even in the anhepatic phase of LT and is cost effective compared to standard intravenous HBIG.